OVAS vs. ZYME, CMRX, CDMO, SBTX, MENS, MBX, RVNC, CKPT, AVTE, and TSVT
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Jyong Biotech (MENS), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), and 2seventy bio (TSVT).
OvaScience vs. Its Competitors
OvaScience (NASDAQ:OVAS) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
In the previous week, Zymeworks had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Zymeworks and 0 mentions for OvaScience. Zymeworks' average media sentiment score of 0.34 beat OvaScience's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.
22.5% of OvaScience shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 7.4% of OvaScience shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
OvaScience has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Zymeworks has a net margin of -182.75% compared to OvaScience's net margin of -10,128.37%. Zymeworks' return on equity of -23.00% beat OvaScience's return on equity.
OvaScience has higher earnings, but lower revenue than Zymeworks.
Zymeworks has a consensus price target of $21.00, indicating a potential upside of 63.04%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than OvaScience.
Summary
Zymeworks beats OvaScience on 11 of the 15 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
This page (NASDAQ:OVAS) was last updated on 7/15/2025 by MarketBeat.com Staff
Free OVAS Stock Alerts